9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Market cap: $7.3M (2/10/2026)
Price: $0.20
Unique Oncolytic Virus Therapies for Multiple Solid Tumors January 2026
Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Other Events
Theriva Biologics Files Prospectus Supplement for $2.89M Common Stock Sale
Theriva Biologics, Inc. Files Prospectus Supplement for $4.02M Stock Sale
VIRAGE trial on Nab-Paclitaxel & Gemcitabine for mPDAC
Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Definitive Revised Proxy Statement
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload